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Ovarian cancer is the fifth most common cause of cancer death in women and the leading cause of death from
gynaecological malignancies. Of the 75% women diagnosed with locally advanced or disseminated disease, only
30% will survive five years following treatment. This poor prognosis is due to the following reasons: limited
understanding of the tumor origin, unclear initiating events and early developmental stages of ovarian cancer, lack
of reliable ovarian cancer-specific biomarkers, and drug resistance in advanced cases. In the past, in vitro studies
using cell line models have been an invaluable tool for basic, discovery-driven cancer research. However, numerous
issues including misidentification and cross-contamination of cell lines have hindered research efforts. In this study
we examined all ovarian cancer cell lines available from cell banks. Hereby, we identified inconsistencies in the
reporting, difficulties in the identification of cell origin or clinical data of the donor patients, restricted ethnic and
histological type representation, and a lack of tubal and peritoneal cancer cell lines. We recommend that all cell
lines should be distributed via official cell banks only with strict guidelines regarding the minimal available
information required to improve the quality of ovarian cancer research in future.
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Epithelial ovarian cancer (EOC) is the fifth most common
cause of cancer death in women and the leading cause of
death from gynaecological malignancies [1]. Survival rates
have changed little since the early 1980’s despite the use of
new chemotherapeutical drugs, with only 40% of all stages
and 15-30% of patients with widespread metastatic disease
surviving 5 years after the initial treatment [2]. This poor
overall prognosis is the result of a combination of factors
including a lack of distinctive symptoms and sensitive/spe-
cific tumour markers at an early stage, drug resistance for
advanced disease, and a limited understanding of the early-
initiating events and early stages of EOC development.
The dualistic paradigm
Among the different tumours arising from the ovary
90% are of epithelial origin [3]. The major histotypes
(serous, endometrioid, mucinous, and clear cell) are* Correspondence: viola.heinzelmann@usb.ch
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unless otherwise stated.partly genetically distinguishable as shown by various
high-throughput studies in the past fifteen years [4]. Re-
cent findings suggest that epithelial tumours of the
ovary may be grouped on the basis of their genetic alter-
ations into a dualistic model that subdivides the various
histological types of EOC into two broad categories.
The slowly developing tumours (Type I) include low
grade serous, endometrioid, mucinous, and a subset of
clear cell carcinomas [5-7] and are characterised by gen-
etic alterations in KRAS, BRAF, CTNNB1, PTEN,
ARID1A, FBXW74, PIK3CA, PPP2R1A, and TGFBR2
[7-12]. The more aggressive Type II tumours harbour mu-
tations in TP53, BRCA1, and BRCA2 [8]. A more system-
atic characterization of Type II tumours, in particular high
grade serous ovarian cancers, was performed by The Can-
cer Genome Atlas (TCGA). The Profiling of 489 samples
for differential mRNA and miRNA expression, DNA copy
number changes, promoter DNA methylation, and whole
exome DNA sequencing revealed that almost all samples
comprised TP53 mutations and significantly recurring
somatic mutations in NF1, BRCA1, BRCA2, RB1, and
CDK12 [13].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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possible tumour origins
The monolayer of epithelial cells covering the outer surface
of the ovary (OSE) has traditionally been thought to be the
site of origin of epithelial ovarian cancer [1]. This is sup-
ported by a recent study focusing on a stem cell niche lo-
cated at the hilum region and a transitional area between
OSE, mesothelium and tubal epithelium. In a comprehen-
sive experimental mouse model the authors demonstrate
that stem cell-like OSE cells have the potential to develop
into EOC [14]. Another theory proposes the normal epi-
thelium of the fallopian tube (serous), endometrium (endo-
metrioid) and endocervix (mucinous) as the origin of the
respective EOC histotypes [15,16]. According to the con-
cept of extra-uterine Müllerian epithelium, the fallopian
tube fimbria is proposed to be the primary origin of the
high grade serous ovarian carcinoma, the most common
EOC subtype and frequently harbouring TP53 and IL-6
mutations [17,18]. This is supported by the presence of
early neoplastic serous tubal intraepithelial lesions (STIL)
in prophylactically removed fallopian tubes of BRCA
mutations-carrying women [19-21]. Those tubal fimbria
displayed characteristic features such as TP53 mutations,
DNA damage, and secretory cells, suggesting the tubal fim-
bria as the precursor for high grade serous ovarian cancers
[20,22,23]. This was further supported by more recent
studies identifying the tubal secretory cells as potential
neoplastic precursors at the tubal fimbria. These cells
carry TP53 mutations, show elevated γH2AX expres-
sion, a marker of DNA damage, and express Ki-67 and
PAX2, two proliferation markers also expressed in serous
tubal intraepithelial carcinomas and high grade serous
ovarian carcinomas [24-27]. In contrast, epithelial-specific
marker such as Calretinin and PAX8 do not seem suitable
in the proof of EOC origin [28]. Recently, it has been dem-
onstrated in a Brca, Tp53, Pten genetic mouse model that
de novo high grade serous ovarian carcinoma are origi-
nated from the fallopian tube secretory epithelium and
that these tumours are correlated with high grade serous
carcinoma tumour markers and genomic alterations of the
human TCGA data set [29].Table 1 Ovarian cancer cell line banks
ID Name
ATCC American Type Culture Collection
ECACC European Collection of Cell Cultures, a part of the He
Protection Agency
DSMZ German Collection of Microorganisms and Cell Cultur
JCRB Japanese Collection of Research Bioresources
CellBank Australia Australian cell bank – Cell Bank Australia
NCBI National Cell Bank of IranSerous carcinomas of the ovary, tube and peritoneum
Serous ovarian- (SOC), tubal- (STC), and peritoneal- (SPC)
cancers are remarkably similar in term of morphology
[30,31], genetics [32], and clinical behaviour and epidemi-
ology [33]. SPC and SOC patients also have a comparable
survival rate that, however, is markedly distinct from that of
patients with low grade SOC metastasizing to distant loca-
tions. Cell lines have long been considered important and
useful in vitro models to investigate the molecular nature
and the pathological processes underlying the develop-
ment of ovarian, tubal, and peritoneal tumours, and their
progression to advanced diseases, and even to search for
diagnostic or prognostic tumour markers as well as for
therapeutic targets.
Ovarian cancer cell lines need better characterization
Falling short of the use of in vivo animal models, cancer
cell lines as in vitro models have proven invaluable experi-
mental tools for many decades in basic research. Cancer
cell lines can be grown continuously in culture, allowing
countless experiments to be performed without the neces-
sary restrictions required for in vivo models. However, due
to few regulations for the development and testing of
these cell lines, the question arises as to the quality of
long-time established ovarian cancer cell lines. Often la-
boratories obtain cell lines from collaborating groups and
trust in their identification of cells. Conducting research
on the basis of such cell lines means not only a waste of a
great deal of money and time but also a risk to steer re-
search in an undesired direction.
It is therefore of great importance to define and establish
a world-wide standard applicable to all cell lines that are
commercially available for research, in order to ensure
that only high-quality cancer cell lines with an unequivo-
cal molecular identity and source are distributed to the re-
search community.
We performed a web search for currently available
banks for cells and cell lines using the terms ‘cell bank’,
‘cell lines’, and ‘cell line bank’. Only web pages in English
and containing normal or cancer ovarian, tubal, and







Table 2 Human cell lines originated from ovarian cancer or human ovarian surface epithelium
ID number Cell line Origin Source
Homo sapiens – human
1 222
2 2008 Ovary
3 2008/C13.R Ovarian adenocarcinoma NCBI
4 41Ma/OAW28 Ovarian cancer ascites ECACC
5 41 M cisR Ovarian cancer ascites
6 59 M Ovarian cancer ascites ECACC
7 A2780 Ovarian adenocarcinoma ECACC
8 A2780ADR Ovarian adenocarcinoma; A2780 ECACC
9 A2780cis Ovarian adenocarcinoma; A2780 ECACC
10 A2780 CP Ovarian adenocarcinoma NCBI
11 A2780 S Ovarian adenocarcinoma NCBI
12 Caov-3 Ovarian adenocarcinoma ATCC
13 Caov-4 Metastatic fallopian tube mass from ovarian tumour ATCC/NCBI
14 CH1 Ovarian adenocarcinoma
15 CH1cisR Ovarian adenocarcinoma
16 COLO-704 Metastatic colonic ascites from ovarian tumour DSMZ
17 COV318 Ovarian cancer ascites ECACC
18 COV362 Ovarian cancer pleural effusion ECACC
19 COV362.4 Ovarian cancer pleural effusion; COV362 ECACC
20 COV413A Metastatic sigmoid mass from ovarian tumour ECACC
21 COV413B Metastatic bladder dome mass from ovarian tumour ECACC
22 COV434 Ovarian granulosa tumour from a solid primary tumour ECACC
23 COV504 Ovarian pleural effusion ECACC
24 COV644 Ovarian cancer (primary tumor) ECACC
25 EFO-21 Ovarian cancer ascites DSMZ
26 EFO27 Metastatic omental mass from ovarian tumour DSMZ
27 ES-2 Ovarian adenocarcinoma ATCC
28 FU-OV-1 Malignant ovarian mass DSMZ
29 HAC-2 Ovarian cancer cell derived from mesonephros JCRB
30 Hey-A8 Ovary CCLE
31 HOSE 6-3 Ovarian surface epithelium
32 HOSE 17-1 Ovarian surface epithelium
33 HOSE 105 Ovarian surface epithelium
34 HOSE 111 Ovarian surface epithelium
35 HOSE 129 Ovarian surface epithelium
36 HOSE 130 Ovarian surface epithelium
37 Hs 38.T Ovarian teratoma ATCC
38 Hs 571.T Ovarian adenocarcinoma ATCC
39 Hs904.T
40 IGROV1 Ovarian adenocarcinoma
41 JHOC-5 Ovarian adenocarcinoma CCLE
42 JHOM-1 Ovarian adenocarcinoma CCLE
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Table 2 Human cell lines originated from ovarian cancer or human ovarian surface epithelium (Continued)
43 JHOM-2B Ovarian adenocarcinoma CCLE
44 JHOS-2 Ovarian adenocarcinoma CCLE
45 JHOS-4 Ovarian adenocarcinoma CCLE
46 KURAMOCHI Ovarian cancer ascites JCRB
47 MCAS Ovarian adenocarcinoma JCRB
48 NCC-OvC-K119 Ovarian adenocarcinoma JCRB
49 OAW28/41 M Ovarian cancer ascites ECACC
50 OAW42 Ovarian cancer ascites ECACC
51 OC 314 Ovarian cancer ascites CCLE
52 OC 315 Ovarian adenocarcinoma CCLE
53 OC 316 Ovarian cancer ascites CCLE
54 ONCO-DG-1a Ovarian adenocarcinoma DSMZ
55 OV-7 Ovarian adenocarcinoma derived from solid tumour ECACC
56 OV17R Ovarian cancer ascites ECACC
57 OV56 Ovarian cancer ascites ECACC
58 OV-58 Ovarian cancer ascites ECACC
59 OV-90 Ovarian cancer ascites ATCC
60 OV-1063a
61 OVC1-PI 32 Ovary NCBI
62 OVCAR-3 Ovarian cancer ascites ATCC/NCBI
63 OVCAR-4 Ovarian adenocarcinoma CCLE
64 OVCAR-8 Ovarian adenocarcinoma CCLE
65 OVISE Metastatic ovarian adenocarcinoma JCRB/CCLE
66 OVK18 Ovarian adenocarcinoma CCLE
67 OVKATE Ovarian adenocarcinoma JCRB
68 OVMANA Ovarian adenocarcinoma JCRB
69 OVMIUa Ovarian adenocarcinoma JCRB
70 OVMIU-IIa Ovarian adenocarcinoma JCRB
71 OVSAHO Ovarian adenocarcinoma JCRB
72 OVSAYOa Ovarian adenocarcinoma JCRB
73 OVTOKO Ovarian adenocarcinoma JCRB
74 PA-1 Ovarian cancer ascites ATCC/JCRB/ECACC
75 PA-1/6TG-r Ovarian cancer ascites JCRB
76 PEA1 Ovarian cancer pleural effusion ECACC
77 PEA2 Ovarian cancer ascites ECACC
78 PEO1 Ovarian cancer ascites ECACC
79 PEO4 Ovarian cancer pleural effusion ECACC
80 PEO6 Ovarian cancer ascites ECACC
81 PEO14b Ovarian cancer ascites ECACC
82 PEO16 Ovarian cancer ascites ECACC
83 PEO23b Ovarian cancer ascites ECACC
84 RKN Ovarian adenocarcinoma JCRB
85 RMG-Ia Ovarian adenocarcinoma JCRB
86 RMG-II Ovarian adenocarcinoma JCRB
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Table 2 Human cell lines originated from ovarian cancer or human ovarian surface epithelium (Continued)
87 RMUG-La Ovarian adenocarcinoma JCRB
88 RMUG-S Ovarian adenocarcinoma JCRB
89 RTSGc Ovarian adenocarcinoma JCRB
90 SCC60
91 SK-OV-3 Ovarian cancer ascites ATCC/NCBI/ECACC
92 SNU-8 Ovarian adenocarcinoma CCLE
93 SNU-119 Ovarian adenocarcinoma CCLE
94 SNU-840 Ovarian adenocarcinoma CCLE
95 SW 626 Ovarian metastatic mass from colon tumour ATCC/ECACC
96 TE 84.T Ovarian adenocarcinoma ATCC
97 TO14b Metastatic omental mass from ovarian tumour ECACC
98 TOV-21G Malignant ovarian mass ATCC
99 TOV-81D Malignant ovarian mass
100 TOV-112D Malignant ovarian mass ATCC
101 TYK-nu Ovarian adenocarcinoma JCRB
102 TYK-nu.CP-r Ovarian adenocarcinoma JCRB
103 UC1-101 Ovarian adenocarcinoma
104 UC1-107
aPossible cross contamination or misidentification (JCRB, DSMZ: Database of Cross-Contaminated or misidentified cell lines, Capes-Davis, A. and Freshney, R.I.
Version 6.7, Table 1 27.6.2011). Cross contaminated with OVCAR-3 (ONCO-DG-1); bAll these cell lines were derived from the same patient.
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trieve references provided by these cell banks reporting
additional details of the stocked cell lines. We also in-
cluded a recent publication in which the copy-number
changes, mutations, and mRNA expression profiles in
ovarian cancer cell lines were compared to those of high
grade SOC (TCGA, http://cancergenome.nih.gov/) [34].
Commercially available ovarian cancer cell lines
Five cell banks worldwide that stock and distribute nor-
mal and/or ovarian cancer cell lines were identified.
These are the American Type Culture Collection (ATCC),
the European Collection of Cell Cultures (ECACC), the
German Collection of Microorganisms and Cell Cultures
(DSMZ), the Japanese Collection of Research Bioresources
(JCRB), and the National Cell Bank of Iran (NCBI)
(Table 1). Remarkably, the Australian cell bank (Cell Bank
Australia) does not stock ovarian cell lines.
Our search algorithm retrieved 153 cell lines. ECAAC
distributes almost 40% of all publicly available cell lines,
followed by JCRB (19%). A number of cell lines (7.2%) are
distributed by two or more cell banks. A listing of the ID
number, cell line designation (name), origin, and source of
the retrieved normal and malignant ovarian, tubal, and
peritoneal cell lines is presented in Tables 2 and 3. About
two thirds (68.0%) of the normal and ovarian cancer cell
lines used in research is of human and about one fourth
(23.5%) of Chinese hamster (Cricetulus griseus) origin.
About 3% originate from mice (Mus musculus) and 4.5%from various species such as Spodoptera frugiperda (Fall
armyworm), Esox lucius (Northern pike fish), Ictalurus
punctatus (Channel catfish), and Sus domesticus (Domes-
tic pig). Strikingly, one third of the 104 described human
ovarian cancer-derived cell lines were in reality not from
ovarian tissue but from peritoneal ascites (21.2%), pleural
fluid (3.8%), or metastatic masses (6.7%).
It is noteworthy that cell line banks do not stock human
cell lines described originating from primary tubal or peri-
toneal origin. However, only recently the isolation and cul-
turing of normal ovarian and fallopian tube epithelial cells
from the same healthy female has been described [35]. This
finding may fill the current gap of knowledge and may help
clarifying the apparent ambiguity of the origin of ‘ovarian
cancer’ and enabling a clear distinction among ovarian,
tubal, and peritoneal cancer at their later stages. However,
peritoneal cell lines are still not available as are a subset of
histologically distinct ovarian cancer cell lines such as bor-
derline cancers, cystadenomas and carcinosarcomas.
The re-naming of cell lines causes constant confusion as
respective annotations are often not found in cell banks.
For example, 41 M cells are the same as OAW28 cells.
Some cell lines have similar names and require caution in
the selection of the cell line of choice: a majority of the ani-
mal cell lines and several human cell lines are derived from
a parental line (e.g. A2780, CHO) and have been modified
in vitro to display chemo resistance (e.g. cisplatin-resistant
A2780CP) or different cellular factors. In addition, the veri-
fication of information given by the cell bank is difficult,
Table 3 Non-human cell line originated from the ovary
Cricetulus griseus – Chinese hamster
105 A2 Ovary ECACC
106 A2H Ovary; A2 ECACC
107 AR-EcoScreen Ovary JCRB
108 CHO Ovary ECACC/NCBI
109 CHO 1–15 500 Ovary NCBI
110 CHO CD28 Ovary NCBI
111 CHO-CHRM1 Ovary; CHO-K1 ECACC
112 CHO-CHRM2 Ovary; CHO-K1 ECACC
113 CHO-CHRM5 Ovary; CHO-K1 ECACC
114 CHO DG-44 Ovary NCBI
115 CHO/dhFr- Ovary ECACC/DSMZ/NCBI
116 CHO/dhFr- Ac-free Ovary; CHO/dhFr- ECACC
117 CHO-FFAR2 Ovary; CHO-K1 ECACC
118 CHO-GPR120 Ovary; CHO-K1 ECACC
119 CHO/HGPRT Ovary JCRB
120 CHO (His9) Ovary JCRB
121 CHO-K1 Ovary; CHO ECACC/JCRB/DSMZ
122 CHO-K1/SF Ovary; CHO-K1 ECACC
123 CHO-OPRL1 Ovary; CHO-K1 ECACC
124 CHO (pMAM-HSluc) Ovary JCRB
125 CHO (pMAM-luc) Ovary JCRB
126 CHO Protein-Free Ovary; CHO ECACC
127 CHO-SSTR1 Ovary; CHO-K1 ECACC
128 GRL101 (KC7) Ovary ECACC
129 GRL101 (MIX) Ovary ECACC
130 M1WT3 Ovary; CHO-K1 ECACC
131 NCTC 4206 Peritoneum; B14FAF28-G3 ECACC
132 P22 Ovary ECACC
133 RR-CHOKI Ovary; CHO-K1 ECACC
134 T02J-7/10 (CHO-M3 (CHRM3)) Ovary; CHO-K1 ECACC
135 T02J-9/10 (CHO-H2 (HRH2)) Ovary; CHO-K1 ECACC
136 T02J-10/10 (CHO-GCGR (GCGR)) Ovary; CHO-K1 ECACC
137 T26J-1/09 (CHO-Beta-2 (ADRB2)) Ovary; CHO-K1 ECACC
138 T35J-5/09 (CHO-FFAR3 (FFAR3)) Ovary; CHO-K1 ECACC
139 UT-1 Ovary; CHO-K1 ECACC
140 XrS6 Ovary; CHO-K1 ECACC
141 Xrs6-hamKu80 Ovary; CHO-K1 ECACC
Mus musculus – mouse
142 OV3121 Ovary JCRB
143 OV3121-ras4 Ovary JCRB
144 OV3121-ras7 Ovary JCRB
145 p53-def-MOSE Ovary JCRB
146 T-Ag-MOSE Ovary JCRB
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Table 3 Non-human cell line originated from the ovary (Continued)
Sus domesticus – Pig
147 AVG-16 Ovary follicle ECACC
Spodoptera frugiperda – fall army worm
148 Sf 9 Pupal ovary NCBI/ECACC
149 Sf 9 TitreHigh AC free Pupal ovary; Sf 9 CL ECACC
150 Sf 21 Pupal ovary NCBI/ECACC
151 Sf 21 TitreHigh AC free Pupal ovary; Sf 21 CL ECACC
Esox lucius – Northern pike fish
152 PG Ovary ECACC
Ictalurus punctatus – channel catfish
153 CCO Ovary ECACC
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tions and their depositors are rarely mentioned.
One apparent shortcoming is that the ethnicity of the
ovarian cancer patient from whom the tumour is de-
rived is indicated in only 30.5%. Apart from the JCRB cell
bank where all the deposited cell lines were derived from
Japanese females (48.3%), the majority of samples where
ethnical details are provided were from Caucasian females.
Since we know that different ethnic groups can have a
propensity for specific genetic mutations, for example in
the BRCA and APC genes of Ashkenazi Jews [36,37], it
is extremely important to have cell lines that represent
the spectrum of ethnic groups around the world. This
will reduce the risk of an ethnic bias and ensure that re-
search into different ethnic groups will allow the most
benefit for these patients.The role of genetic changes in the characterization of
ovarian cancer cell lines
The (molecular) characterization of EOC in the clinics sig-
nificantly depends on the presence and type of genetic al-
terations in the cancer and may define the treatment
options and the patients’ outcome. The tumor origin where
the cell lines derived from was not precisely provided in
51.2% (Table 4). Considering the clinico-pathological (histo-
type, FIGO stage, grade) as essential criteria to categorize
EOC in type I and II tumours, the respective information
provided by cell banks is not sufficient. The data review on
available human ovarian cancer cell lines (n = 95) reflects
that cell banks provide the histological subtype in 76.8%
with discrepancies to original publications (Table 5), stage
in 34.7%, and the initial grade in only 20%. In contrast, the
information on chemotherapy resistance is provided ad-
equately. Epithelial (−like) cells are characterized with epi-
thelial or stromal markers in more than half (57.9%) of all
cell lines, and out of these 85.4% had at least epithelial-like
features. Another essential criterion is the doubling time
that is provided in only 29.5%.We also collected and evaluated data provided by cell
banks in regards to molecular markers. This information
was very limited and only few cell lines were evaluated for
expression of progesterone (7.4%) and oestrogen (6.3%) re-
ceptors, vimentin (5.3%), TP53 mutations (4.2%), Her2/
neu (3.2%), EpCAM (3.2%), and cytokines 7, 8, 17, 18, and
19 (ranging from 5.3% to 8.4%).
Potential risks of the use of cell lines for in vitro research
The misidentification and cross-contamination of cell lines
is problematic in research and may increase the risk for
false results and misinterpretations. The extent of misiden-
tification is documented in a recent study wherein a panel
of ovarian and endometrial cell lines was analysed by DNA
profiling [38]. The authors found that 8 out of the 51 ovar-
ian cancer cell lines were in fact breast cancer, terato-
carcinoma, or cervical cancer cell lines and that2
normal endometrial cancer cells were in fact HeLa cer-
vical cancer or MCF-7 breast cancer cells. Likewise,
cross-contamination of cell lines, i.e. the accidental gener-
ation of mixed cell cultures, is not a lesser problem. Jäger
et al. 2013 reported that the popular and frequently used
KU7 urothelial carcinoma cell line was cross-contaminated
years ago with HeLa cells [39]. Cross-contaminations may
occur when multiple cell lines are cultured simultaneously
(a practice that should be avoided) and becomes only ap-
parent if multiple morphologies are suddenly observed but
fatally remains unnoticed if cells have indistinguishable
morphology.
Bacterial/fungal/yeast/mycoplasma contamination pre-
sents another problem adversely affecting research results.
Of these, mycoplasma species are most likely to be detri-
mental to cell functioning. Unlike most bacterial, fungal or
yeast infections, mycoplasma are macroscopically and
microscopically undetectable; it may remain in culture for
extended periods of time affecting cell growth, gene ex-
pression and overall cell functioning [40]. This may be one
reason for why different research groups report contra-
dictory findings. For this reason, Cell Bank Australia has
Table 4 Origin of human ovarian cancer cell lines
Origin specified (cell line banks)
Ascites Metastasis Ovary Pleural effusion
Origin specified (original references)
Ascites 9 0 5 0
Metastasis 0 2 6 0
Not specified 0 0 11 0
Ovary 0 0 9 0
Pleural effusion 0 0 0 1
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identified cell lines based on the literature. Other cell
banks such as the JCRB have also made an effort to screen
the database and identified which of their own cell lines
were originally misidentified (Table 1).
The unavailability of a considerable number of in vitro
cell line models to the research community is also an issue.
The problem is two-fold: firstly, there is no quality control
of cells generated in individual laboratories when they are
not deposited in a professional cell bank. Even when these
cells are meticulously generated and cultured, independent
quality checks and verifications are not possible. This flaw
is overcome by directly contacting the laboratory where
the cell lines were generated. This, however, can lead to
the second problem; the passing on of cell lines from la-
boratory to the other, thereby bypassing the critical quality
control cell banks. In the past it has been common practice
to obtain cells from collaborating groups, and with the re-
quired permission, to again distribute these to other la-
boratories. Whilst this practice is in the spirit of research
collaborations, it increases the risk of receiving contami-
nated or misidentified cell lines that, in turn, can be detri-
mental to research.
Conclusions
To ensure a unique quality of cancer research around the
world we recommend that all cell lines used for research
should be deposited in a cell bank and be readily access-
ible for all researchers. Ovarian cancer cell bank operators
should provide development protocols and comprehensive
clinical data for all commercially available cell lines.Table 5 Histotypes of human ovarian cancer cell lines
Clear cell E







Unknown 0Depositors of cell lines should ensure that they have care-
fully collected all relevant clinical information from the
donor individuals. This information includes: the exact
origin of the cells, the stage during disease progression the
cells were taken, the type of therapy the patient underwent
prior to sample collection, the data on the patient’s sur-
vival, the ethnicity and family history (including known
genetic alterations), and the preoperative plasma CA125
levels currently provided by only 5.3% of all human ovar-
ian cancer cell lines. Additionally, we recommend that all
cell bank operators conform to the same style of reporting
the cell line information and only bank cells where all ne-
cessary information is available. This will ensure that the
highest standard of research is maintained worldwide.
Short tandem repeat (STR) profiling, a highly-sensitive
method to detect cellular cross-contamination, should be
performed by researchers for all newly generated cell lines
and should be confirmed by the cell bank once deposited
and prior to the sale of the cells. The service for STR pro-
filing is provided by various laboratories, e.g. American
Type Cell culture Collection (ATCC-USA, http://www.atcc.
org), China Center for Type Culture Collection (CCTCC,
http://www.cctcc.org), Australian Cell Bank (http://www.
cellbankaustralia.com), European Culture Collection of
Cell Cultures (ECACC, http://www.hpacultures.org.uk), or
German Cell Culture Collection (DSMZ, http://www.dsmz.
de). From a recent study that histotyped standard ovarian
cancer cell lines by short tandem repeats, immunohisto-
chemistry, and mutation analysis it was concluded that the
knowledge of the mutation status of cancer genes such as
ARID1A and TP53 and of the general immunoprofileOrigin specified (cell line banks)
ndometrioid Mixed Mucinous Other Serous Unknown
0 0 0 0 0 0
2 0 0 0 0 0
0 1 0 0 0 1
0 0 3 2 0 0
0 0 0 3 0 0
0 0 1 6 7 1
0 0 0 7 0 1
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of ovarian cancer cells [41]. Following the model of the
Cancer Cell Line Encyclopedia (CCLE), we suggest the es-
tablishment of a centralized cell line database that would
harbour all the relevant details of new cell lines and would
be updated with new details in real time as experimental
results are reported in the literature. This is believed to re-
duce the overlap of research performed and to continually
improve the quality and appropriateness of future cell line
studies. A cell bank professional with expertise in cancer
research would be beneficial for researchers who need ad-
vice in correctly choosing the cell line appropriate for a
specific research question. The expansion of the current
offer of cell lines deposited in the cell banks by additional
types of cells is desirable. These include primary, recurrent
and metastatic ovarian-, tubal- and peritoneal cancers, a
set of cell lines representing all known EOC histotypes,
age-matched normal control OSE and tubal cells, and cell
lines derived from primary, recurrent and metastatic tu-
mours from the same patients at different progression
time points. It is clear that worldwide collaborative efforts
are to be taken to reach these recommendations, but we
believe that this will be of benefit for the research results
in the future.
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